Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pegbin + ACT580 + ACT201
- Development stage
- Preclinical
- Lead developer
- Xiamen Tebao Biological Engineering
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Subcutaneous
01
Overview
Pegbin + ACT580 + ACT201 is an investigational triple combination therapy being developed by Amoytop Biotech (Tebao Biotech) in collaboration with Aligos Therapeutics for the treatment of chronic hepatitis B (CHB). The combination consists of Pegbin (peginterferon alfa-2b), a long-acting recombinant interferon; ACT580 (pevifoscorvir sodium, formerly ALG-000184), an oral small molecule capsid assembly modulator (CAM-E); and ACT201 (ALG-170675), an antisense oligonucleotide (ASO) that targets HBV RNA and acts as a Toll-like receptor 8 (TLR8) agonist. This triple regimen is designed to achieve a functional cure for chronic hepatitis B by combining three complementary mechanisms: potent inhibition of viral replication and prevention of cccDNA replenishment (via ACT580), rapid reduction of hepatitis B surface antigen (HBsAg) levels (via ACT201), and robust immune-mediated clearance of infected hepatocytes (via Pegbin).
- Other names
- Pegbin + ALG-000184 + ACT201Pegbin + ALG-000184 + ALG-170675Pegbin + pevifoscorvir sodium + ACT201Pegbin + pevifoscorvir sodium + ALG-170675peginterferon alfa-2b + ALG-000184 + ACT201peginterferon alfa-2b + ALG-000184 + ALG-170675peginterferon alfa-2b + pevifoscorvir sodium + ACT201peginterferon alfa-2b + pevifoscorvir sodium + ALG-170675
02
Targets
HBc (Hepatitis B virus core protein)IFNAR1 (Interferon alpha/beta receptor 1)IFNAR2 (Interferon alpha/beta receptor subunit 2)TLR8 (Toll-like receptor 8)
Beyond the preview
Go deeper on Pegbin + ACT580 + ACT201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pegbin + ACT580 + ACT201.